ERBB inhibitors, potentially in combination with RAF inhibitors, may prove useful in the setting of acquired resistance to RAF inhibitors in BRAF V600-mutant melanoma [54–58], but acquired resistance to first-line therapy was not a focus of our study. Here, EGFR is linked to melanoma.